Korean Circ J.  2017 May;47(3):318-319. 10.4070/kcj.2017.0066.

PCI or CABG, That is the Question!

• Woo JS
• Kim W

• KMID: 2385385
• DOI: http://doi.org/10.4070/kcj.2017.0066

Abstract

No abstract available.

Reference

1. Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines and the society for cardiovascular angiography and interventions. J Am Coll Cardiol. 2011; 58:e44–e122.

2. Kang SH, Lee CW, Yun SC, et al. Bypass grafting versus drug-eluting stent implantation for multivessel disease in patients with chronic kidney disease. Korean Circ J. 2017; 47:354–360.

3. Charytan DM, Desai M, Mathur M, et al. Reduced risk of myocardial infarct and revascularization following coronary artery bypass grafting compared with percutaneous coronary intervention in patients with chronic kidney disease. Kidney Int. 2016; 90:411–421.

4. Wang ZJ, Zhou YJ, Liu YY, et al. Comparison of drug-eluting stents and coronary artery bypass grafting for the treatment of multivessel coronary artery disease in patients with chronic kidney disease. Circ J. 2009; 73:1228–1234.

5. Ashrith G, Lee VV, Elayda MA, Reul RM, Wilson JM. Short- and long-term outcomes of coronary artery bypass grafting or drug-eluting stent implantation for multivessel coronary artery disease in patients with chronic kidney disease. Am J Cardiol. 2010; 106:348–353.

6. Bangalore S, Guo Y, Samadashvili Z, Blecker S, Xu J, Hannan EL. Revascularization in patients with multivessel coronary artery disease and chronic kidney disease: everolimus-eluting stents versus coronary artery bypass graft surgery. J Am Coll Cardiol. 2015; 66:1209–1220.

7. Palmer SC, Di Micco L, Razavian M, et al. Antiplatelet agents for chronic kidney disease. Cochrane Database Syst Rev. 2013; (2):CD008834.

8. James S, Budaj A, Aylward P, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the platelet inhibition and patient outcomes (PLATO) trial. Circulation. 2010; 122:1056–1067.

9. Jeong KH, Cho JH, Woo JS, et al. Platelet reactivity after receiving clopidogrel compared with ticagrelor in patients with kidney failure treated with hemodialysis: a randomized crossover study. Am J Kidney Dis. 2015; 65:916–924.